Further evidence against the use of aminoglycosides in cirrhotic patients.
García-Tsao
G
G
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D009428:Netilmicin / Q000008:administration & dosage / Q000009:adverse effects*; D018805:Sepsis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D009428:Netilmicin; D002442:Ceftazidime